Evidence map›Paper›PMID 19169831›Full record

ReviewCurrent treatment options in oncology2009

Chronic lymphocytic leukemia: new concepts and emerging therapies.

Tahamtan Ahmadi, Tapan Maniar, Stephen Schuster, Edward Stadtmauer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. A new cellular weapon to kill leukaemic B-cells.Sultan Qaboos University medical journal · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tahamtan AhmadiHematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Tapan Maniar
Stephen Schuster
Edward Stadtmauer
California University of Pennsylvania · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementRemarkable progress in elucidating the biology of chronic lymphocytic leukemia (CLL) has been made over the last two decades. Improved understanding of CLL has lead to new prognostic tools and therapeutic options, and holds promise for eventually finding a cure for this disease. Challenges lie in incorporating the various treatment modalities, including chemotherapy, monoclonal antibodies, immunotherapeutic strategies and novel small molecules, into a comprehensive treatment strategy guided by the biological complexity of CLL.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideB-Lymphocyte SubsetsCD5 AntigensDisease ProgressionDrugs, InvestigationalHumansImmunologic FactorsImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellMulticenter Studies as TopicNeoplasm, ResidualNitrogen Mustard CompoundsPrognosisRandomized Controlled Trials as TopicAntibodies, MonoclonalBendamustine HydrochlorideCD5 AntigensDrugs, InvestigationalImmunologic FactorsNitrogen Mustard Compounds

Identifiers

PMID19169831
OpenAlexW2025467650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.